Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 124Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Recurrence 18Burkitt Lymphoma 15Lymphoma, Large B-Cell, Diffuse 8Neoplasms, Plasma Cell 7Neoplasms 7Immunoglobulin Light-chain Amyloidosis 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma 6Leukemia, Biphenotypic, Acute 6Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lung Neoplasms 4Leukemia 4Waldenstrom Macroglobulinemia 3Nausea 3Colorectal Neoplasms 3Smoldering Multiple Myeloma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

tocilizumab 2talquetamab 1siltuximab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Dexamethasone × 90 days × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡